S R Hart1, B Green. 1. St Thomas' Hospital, London Royal Sussex County Hospital, Brighton, Sussex.
Abstract
AIMS: To investigate prescribing patterns to prevent steroid induced osteoporosis. To compare prophylactic prescribing with National Osteoporosis Society (NOS) guidelines. METHOD: All patients (n=92) taking oral corticosteroids admitted to general medical wards at a district general hospital were prospectively investigated over a nine month period. RESULTS: Variations from recommended management were revealed. Altogether 64.7% of all inpatients who qualified for prophylaxis for steroid induced osteoporosis were not provided with any suitable agent. It was also found that 21.6% of those who qualified for treatment received a bisphosphonate, the only treatment currently licensed for preventing steroid induced osteoporosis. Of those prescribed prophylactic treatment, a bisphosphonate was selected for 39.3%, hormone replacement therapy was given to 25.0%, and 35.7% received treatment that is not recommended in NOS guidelines. CONCLUSION: This study revealed substantial variations from NOS guidelines. It is suggested that osteoporosis prophylaxis during steroid treatment is promoted by local hospital guidelines, hospital and community pharmacists, audit, and general practitioners.
AIMS: To investigate prescribing patterns to prevent steroid induced osteoporosis. To compare prophylactic prescribing with National Osteoporosis Society (NOS) guidelines. METHOD: All patients (n=92) taking oral corticosteroids admitted to general medical wards at a district general hospital were prospectively investigated over a nine month period. RESULTS: Variations from recommended management were revealed. Altogether 64.7% of all inpatients who qualified for prophylaxis for steroid induced osteoporosis were not provided with any suitable agent. It was also found that 21.6% of those who qualified for treatment received a bisphosphonate, the only treatment currently licensed for preventing steroid induced osteoporosis. Of those prescribed prophylactic treatment, a bisphosphonate was selected for 39.3%, hormone replacement therapy was given to 25.0%, and 35.7% received treatment that is not recommended in NOS guidelines. CONCLUSION: This study revealed substantial variations from NOS guidelines. It is suggested that osteoporosis prophylaxis during steroid treatment is promoted by local hospital guidelines, hospital and community pharmacists, audit, and general practitioners.
Authors: P Sambrook; J Birmingham; S Kempler; P Kelly; S Eberl; N Pocock; M Yeates; J Eisman Journal: J Bone Miner Res Date: 1990-12 Impact factor: 6.741
Authors: R Eastell; D M Reid; J Compston; C Cooper; I Fogelman; R M Francis; D J Hosking; D W Purdie; S H Ralston; J Reeve; R G Russell; J C Stevenson; D J Torgerson Journal: J Intern Med Date: 1998-10 Impact factor: 8.989
Authors: K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis Journal: N Engl J Med Date: 1998-07-30 Impact factor: 91.245
Authors: J D Adachi; W G Bensen; J Brown; D Hanley; A Hodsman; R Josse; D L Kendler; B Lentle; W Olszynski; L G Ste-Marie; A Tenenhouse; A A Chines Journal: N Engl J Med Date: 1997-08-07 Impact factor: 91.245
Authors: Mir Sadat-Ali; Abdulmohsen H Alelq; Badar A Alshafei; Haifa A Al-Turki; Mohammed A Abujubara Journal: Ann Saudi Med Date: 2009 May-Jun Impact factor: 1.526